This is an international Web site for Signifor® (pasireotide) and is intended for healthcare professionals outside the US. The information on the site is not country specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Signifor Information for International Healthcare Professionals Signifor Information for US residents Signifor Information for Patients Outside the US

Summary of Product Characteristics Patient Leaflet Safety Information AAA | Print | Share

U.S. RESIDENTS | This site is intended for healthcare professionals outside the US.

English Español

MOA|Trial Design|Efficacy|Safety|Dosing and Adminstration

HOME ABOUT SIGNIFOR

Signifor is the First Approved Pituitary Targeted Medical Therapy for Cushing's disease

Signifor, a novel multireceptor-targeted somatostatin analogue, binds with high affinity to 4 of the 5 ssts, with the highest affinity for sst5, resulting in inhibition of adrenocorticotropic hormone (ACTH) secretion. Signifor represents the first specific treatment for ACTH-secreting pituitary adenomas and will be the first approved medical treatment for Cushing's disease.1

In this section you will find information about:

Signifor is indicated for the treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.1

References: 1. Signifor Summary of Product Characteristics. Novartis Pharma AG. 2. Colao A, Petersenn S, Newell-Price J, et al. A 12-month, phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366:914-924.

Cushing's Disease

Cushing's disease is a rare hor-
mone disorder. Recent statistics
indicate that annual incidence is
somewhere between 1 and 10
per million.1

Click here
Disclaimer: This is an international Web site for Signifor® (pasireotide) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country specific and may contain information that is outside the approved indications in the country in which you are located.
Novartis Oncology

About Novartis Oncology Contact Us Site Map Use of Web site is governed by the Terms of Use and Privacy Policy
© Novartis AG